- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06850376
COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus
February 26, 2025 updated by: Istituto Auxologico Italiano
This pragmatic trial aims to evaluate whether a weekly self-help virtual reality protocol can help overcome the psychological burden of the COVID-19 pandemic.
The protocol is based on 'The Secret Garden' 360° VR video available online (www.covidfeelgood.com)
which simulates a natural environment to promote relaxation and self-reflection.
The VR experience is combined with daily cognitive and social exercises designed to facilitate critical examination of personal identity, relationships, and coping strategies.
The study assesses whether this intervention can reduce anxiety, depression, perceived stress, and hopelessness while improving well-being and social connectedness during pandemic-related restrictions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Lombardia
-
Milano, Lombardia, Italy, 20145
- IRCCS Istituto Auxologico Italiano
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult participants (≥18 years)
- Native speakers of the country where they will be enrolled
- Have experienced at least two months of quarantine or isolation related to the coronavirus pandemic
- Provide full, written, informed consent
- Have the availability of a smartphone and a cardboard VR headset
- Availability and agreement of a partner for conducting the self-help component of the treatment
Exclusion Criteria:
- Visual or hearing impairments that can limit the participation in the protocol
- Participants reporting vestibular and/or balance disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VR Self-Help Protocol
Participants in this arm receive the 7-day COVID Feel Good self-help protocol immediately upon enrollment.
The intervention consists of daily exposure to the 'Secret Garden' 360° VR video combined with specific daily cognitive and social exercises.
Participants use a VR headset compatible with the Cardboard format to experience the 10-minute VR video once per day for 7 consecutive days, followed by completing the daily exercise with a partner.
|
The intervention consists of a 7-day self-help protocol based on daily exposure to 'The Secret Garden' 360° VR video (10 minutes per day) available at www.covidfeelgood.com,
combined with different daily cognitive and social exercises.
Participants use a smartphone with VR headset compatible with the Cardboard format.
Each day's exercise addresses different psychological aspects: fighting rumination, awakening self-esteem, autobiographical memory, sense of community, goals and dreams, empathy, and planning for change.
Exercises are designed to be performed individually and then discussed with a partner.
|
|
Other: Waiting List Control
Participants in this arm are placed on a waiting list for 7 days before receiving the intervention.
During this waiting period, they complete the same baseline assessments as the experimental group but do not receive any specific intervention.
After the 7-day waiting period, these participants then receive the same 7-day VR self-help protocol.
|
Participants in the control group initially undergo a 7-day waiting period before receiving the VR self-help protocol.
During this period, they complete the same baseline assessments as the experimental group but do not receive any specific intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in depression, anxiety, and stress levels as measured by Depression Anxiety Stress Scale (DASS-21)
Time Frame: Baseline (Day -7 and Day 0), Post-intervention (Day 7), and 2-week Follow-up (Day 21)
|
The Depression Anxiety Stress Scale (DASS-21) is a self-report questionnaire consisting of 21 items divided into three subscales that measure depression, anxiety, and perceived stress.
Each subscale can be computed individually or added together into a score for general distress.
Higher scores indicate greater symptoms of depression, anxiety, and stress.
The scale will be used to assess changes in psychological distress associated with the COVID-19 pandemic before and after the VR self-help intervention.
|
Baseline (Day -7 and Day 0), Post-intervention (Day 7), and 2-week Follow-up (Day 21)
|
|
Perceived Stress Scale (PSS-10)
Time Frame: Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
A scale measuring subjective perception of stress during the past week
|
Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
|
Change in hopelessness levels
Time Frame: Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
A scale measuring pessimistic attitudes toward the future
|
Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in social connectedness
Time Frame: Baseline (Day -7 and Day 0), Post-intervention (Day 7), and 2-week Follow-up (Day 21)
|
A scale measuring sense of connection to others and to the social context
|
Baseline (Day -7 and Day 0), Post-intervention (Day 7), and 2-week Follow-up (Day 21)
|
|
Change in fear of coronavirus
Time Frame: Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
A scale measuring level of fear related to the COVID-19 pandemic
|
Baseline (Day -7 and Day 0), Post-intervention (Day 7), and Follow-up (Day 21)
|
|
Change in relaxation levels during intervention
Time Frame: Daily during intervention (Days 1-7)
|
A scale measuring relaxation and perceived stress during the intervention
|
Daily during intervention (Days 1-7)
|
|
Change in subjective distress during intervention
Time Frame: Daily during intervention (Days 1-7)
|
A scale measuring level of perceived distress
|
Daily during intervention (Days 1-7)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2020
Primary Completion (Actual)
October 1, 2021
Study Completion (Actual)
December 31, 2021
Study Registration Dates
First Submitted
February 26, 2025
First Submitted That Met QC Criteria
February 26, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 26, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 39C001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
Fondation FondaMentalGYNOVNot yet recruitingDepression | Depression in Adults | Depression DisorderFrance
Clinical Trials on COVID Feel Good VR Self-Help Protocol
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); Florida Department of HealthCompleted
-
The University of Hong KongHong Kong Council on Smoking and HealthCompleted
-
Seagen, a wholly owned subsidiary of PfizerCompletedPeripheral T-cell LymphomaUnited States, Spain, United Kingdom, France, Italy